Published online August 1, 2005
PEDIATRICS Vol. 116 No. 2 August 2005, pp. 564-565 (doi:10.1542/peds.2005-0698KKK)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banks, J. R.
Right arrow Articles by Andrews, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Banks, J. R.
Right arrow Articles by Andrews, T.

SUPPLEMENT ARTICLE

Cost-Effectiveness Analysis of Early Intervention With Budesonide in Mild Persistent Asthma

James R. Banks, MD and Timothy Andrews, MD

Arnold, MD

The first 20% of the full text of this article appears below.

Sullivan SD, Buxton M, Andersson LF, et al. J Allergy Clin Immunol. 2003;112:1229–1236


   Purpose of the Study.
 
These investigators analyzed cost-effectiveness of a commonly prescribed inhaled corticosteroid from the perspectives of both direct and indirect costs.


   Study Population.
 
Patients aged 5 to 66 years from 32 countries were enrolled in the Inhaled Steroid as Regular Therapy in Early Asthma (START) study. Patients were eligible if they were diagnosed with asthma within 2 years of randomization and lacked significant comorbidity.


   Methods.
 
START was a randomized, 3-year controlled trial of budesonide versus usual asthma therapy in early-onset asthma among . . . [Full Text of this Article]